Document Detail

Randomized controlled trial of pericardial blood processing with a cell-saving device on neurologic markers in elderly patients undergoing coronary artery bypass graft surgery.
MedLine Citation:
PMID:  16798186     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Processing of pericardial shed blood with a cell-saving device was claimed to prevent lipid microembolization and to protect from neurocognitive dysfunction after cardiopulmonary bypass. The present study tested the hypothesis that processing of pericardial shed blood with a cell-saving device during cardiopulmonary bypass would significantly decrease serum levels of protein S100B, and improve brain oxygen saturation and neurologic outcome, all markers of brain injury in elderly patients. METHODS: Forty patients, 65 years of age and older, undergoing coronary artery bypass graft with cardiopulmonary bypass, were prospectively randomly assigned to processing of pericardial shed blood with a cell-saving device or to conventional use of a standard closed venous reservoir where cardiotomy blood was collected and reinfused through the arterial circuit (control group). Serum in S100B was measured 30 minutes, 4 hours, 24 hours, and 48 hours after surgery. Near-infrared spectroscopy monitoring was performed during the procedure and the National Institutes of Health stroke scale was measured before surgery and at the time of discharge of the hospital. RESULTS: Patients in the cell-saving device group averaged 72 +/- 3 years of age and underwent 3.1 +/- 0.7 coronary artery grafts with a mean of 62 +/- 20 minutes of cardiopulmonary bypass time. Patients in the control group averaged 75 +/- 4 years of age (p = 0.03) and underwent 3.3 +/- 0.6 coronary artery grafts (p = 0.49) with a mean of 75 +/- 25 minutes of cardiopulmonary bypass time (p = 0.12). The quantity of blood administered from the cell-saving device averaged 281 +/- 162 mL per patient. Serum protein S100B levels averaged 0.06 +/- 0.03 before surgery and 0.51 +/- 0.23 microg/L 30 minutes after surgery in the cell-saving device patients compared with 0.076 +/- 0.04 before surgery (p = 0.32) and 1.48 +/- 0.66 (p < 0.0001) in the control patients. The near-infrared spectroscopy baseline mean value of left and right cortical region was 58% +/- 12% and 55% +/- 7% in the cell-saving device group versus 59% +/- 7% and 53% +/- 6% in the control group (p = 0.67 and 0.36), and no difference occurred over time in each group. The National Institutes of Health stroke score before and after surgery was similar in the two groups. There was one cerebrovascular complication in the control group (1 of 20, 5%) after surgery. CONCLUSIONS: The difference between the two groups occurred 30 minutes after surgery, at which time serum levels of protein S100B were significantly higher in the control group compared with cell-saving device patients. Although use of the cell-saving device was not associated with higher brain oxygen saturation nor changes in the National Institutes of Health stroke score, it is associated with lesser release of nonspecific markers of brain injury in elderly patients.
Michel Carrier; André Denault; Joel Lavoie; Louis P Perrault
Related Documents :
16877146 - Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty.
16798186 - Randomized controlled trial of pericardial blood processing with a cell-saving device o...
9263086 - Concentration of cefamandole in plasma and tissues of patients undergoing cardiac surge...
10622296 - Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-...
22077016 - The effectiveness of prolotherapy for recalcitrant medial tibial stress syndrome: a pro...
24429126 - Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodi...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  82     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-26     Completed Date:  2006-08-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  51-5     Citation Subset:  AIM; IM    
Department of Surgery, Biomedical Laboratory, Montreal Heart Institute, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers
Blood Loss, Surgical
Blood Transfusion, Autologous / instrumentation*
Brain / blood supply
Brain Damage, Chronic / prevention & control
Cardiopulmonary Bypass
Coronary Artery Bypass*
Erythrocyte Transfusion
Hypoxia-Ischemia, Brain / prevention & control*
Intracranial Embolism / etiology,  prevention & control
Nerve Growth Factors / blood*
Oxygen / blood
Pilot Projects
Postoperative Complications / prevention & control*
S100 Proteins / blood*
Severity of Illness Index
Surgical Procedures, Elective
Reg. No./Substance:
0/Biological Markers; 0/Nerve Growth Factors; 0/S-100 calcium-binding protein beta subunit; 0/S100 Proteins; 7782-44-7/Oxygen
Comment In:
Ann Thorac Surg. 2006 Jul;82(1):56   [PMID:  16798187 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noninvasive midterm follow-up of radial artery bypass grafts with 16-slice computed tomography.
Next Document:  EuroSCORE predicts immediate and late outcome after coronary artery bypass surgery.